Home News Page 2

News

Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Astellas and Seattle Genetics file BLA for Enfortumab Vedotin

Japanese drugmaker Astellas Pharma and Seattle Genetics confirmed the submission of a Biologics License Application (BLA) for accelerated approval...

5 Things You Need To Know About ADCs This Week – July 15, 2019

In this article I want to discuss the 5 Things happening in the world of ADCs this week that...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

SpringWorks and GlaxoSmithKline to Collaborate in the Development of Belantamab Mafodotin

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer,...

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted...

Anti-CD205 Antibody-Drug Conjugate MEN1309/OBT076 Shows Substantial in vitro Antitumor Activity

Non-clinical study findings published in the journal Molecular Cancer Therapeutics describing the characterization of the anti-CD205 antibody-drug conjugate (ADC)...
WuXi Biologics Conjugation Solution Center

WuXi Biologics Expands Integrated Biologics Conjugation Solution Center

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...
Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

FDA Grants Accelerated Approval of Polatuzumab Vedotin in Select Patients

The U.S. Food and Drug Administration (FDA) today confirmed that it has granted accelerated approval of polatuzumab vedotin-piiq (Polivy™;...
General views from the 2019 Annual Meeting of the American Society (ASCO), held May 31 - June 4, 2019. Courtesy © ASCO/Phil McCarten 2019.

RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial Cancer

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of...
Unlocking ADC Manufacturing Innovation with ADC Bio

Webinar: Predicting And Lowering The Cost Of Antibody Drug Conjugates

ADC Bio and Biopharm will be hosting a live webinar titled, "Predicting and Lowering the Cost of Antibody Drug...

Three U.S. Companies Awarded MilliporeSigma’s Advance Biotech Grant

MilliporeSigma Awards Grants to Biotechs Focused on Traumatic Brain Injury, Vaccine Development and Chronic Pain. MilliporeSigma today announced the...

FEATURED RESOURCES